[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Kuo SF, Chen JY, Chuang WY, Jung SM, Chang YC, Lin JD: Concurrent papillary thyroid cancer with pituitary ACTH-secreting tumor. J Formos Med Assoc; 2007 Apr;106(4):330-5
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent papillary thyroid cancer with pituitary ACTH-secreting tumor.
  • Concomitant thyroid cancer with pituitary tumor is uncommon.
  • This study reports a case of advanced papillary thyroid carcinoma with pituitary adrenocorticotropic hormone (ACTH)-secreting tumor.
  • A 58-year-old male patient had thyroid cancer in 1991 and presented with headache caused by pituitary tumor with apoplexy in 1993.
  • During follow-up for thyroid cancer, (201)thallium scan proved to be an effective tool for detecting metastatic thyroid cancer in the patient without pituitary TSH reserve.
  • Pituitary ACTH-secreting tumor was confirmed in 2001 based on the high serum ACTH level and positive immunohistochemical stain for ACTH.
  • Moreover, serum ACTH levels were 337 and 232 pg/mL with normal serum cortisol and urine-free cortisol.


2. Hashiba T, Saitoh Y, Asanuma N, Kouhara H, Maruo T, Fujinaka T, Kasayama S, Yoshimine T: Reduction of a pancreatic tumor after total removal of an ACTH secreting pituitary tumor: differential diagnosis of Cushing's syndrome. Endocr J; 2006 Apr;53(2):203-8
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of a pancreatic tumor after total removal of an ACTH secreting pituitary tumor: differential diagnosis of Cushing's syndrome.
  • Endocrinologic tests sometimes fail to distinguish adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma from ectopic ACTH-secreting tumor.
  • The authors experienced a case of Cushing's disease associated with a pancreatic tumor.
  • A 54-year-old woman presented with Cushing's syndrome and pancreatic tumor.
  • Magnetic resonance imaging (MRI) failed to reveal a pituitary tumor, but a gadolinium-enhanced tumor with cystic components was seen in the pancreatic tail.
  • Results of conventional endocrinologic tests suggested ectopic ACTH syndrome, but venous sampling including cavernous sinus sampling indicated an ACTH-secreting pituitary adenoma.
  • Transsphenoidal surgery revealed a pituitary microadenoma, and total removal of the tumor was achieved.
  • Postoperative abdominal MRI revealed that the pancreatic tumor diminished gradually without treatment.
  • Selective cavernous sinus sampling was useful for distinguishing ACTH-secreting pituitary adenoma from ectopic ACTH syndrome in this complex case.
  • This was a rare case in which the pancreatic tumor diminished after total removal of the ACTH-secreting pituitary adenoma.
  • [MeSH-major] Adrenocorticotropic Hormone / secretion. Cushing Syndrome / diagnosis. Pancreatic Neoplasms / complications. Pituitary Neoplasms / secretion
  • [MeSH-minor] ACTH Syndrome, Ectopic / diagnosis. Adenoma / secretion. Adenoma / surgery. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Pituitary ACTH Hypersecretion / diagnosis. Positron-Emission Tomography


3. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y: Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J; 2009;56(4):579-84
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
  • Somatostatin analogs and dopamine agonists are clinically used for medical therapy of functioning pituitary tumors, such as growth hormone- and prolactin-secreting tumors, however, their effects on ACTH-secreting tumors are controversial.
  • This study was aimed to determine whether somatostatin receptor (SSTR) subtype (1-5) and dopamine receptor type 2 (D2R) are differentially expressed in pituitary tumors causing Cushing's disease (CD), silent corticotroph adenoma (SCA), and non-functioning pituitary tumor (NFT).
  • Tissue specimens were obtained from 35 pituitary tumors during transsphenoidal surgery.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. Pituitary ACTH Hypersecretion / metabolism. Pituitary Neoplasms / genetics. Receptors, Dopamine D2 / genetics. Receptors, Somatostatin / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318729.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 0 / somatostatin receptor type 1; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


Advertisement
4. Tateno T, Izumiyama H, Doi M, Akashi T, Ohno K, Hirata Y: Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma. Endocr J; 2007 Dec;54(5):777-82
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Silent corticotroph adenoma (SCA) is defined as an ACTH-producing pituitary tumor not associated with clinical and endocrine feartures of Cushing's syndrome, but its underlying molecular mechanism(s) remains unknown thus far.
  • We tested the hypothesis that reduced expression of prohormone convertase (PC) 1/3 responsible for proteolytic processing of proopiomelanocortin (POMC) in SCA may lead to production of unprocessed, biologically inactive POMC and/or precursor of ACTH.
  • Among 30 non-functioning pituitary macroadenomas (NFA) examined, we found 6 SCAs by immunohistochemical study using anti-ACTH antibody.
  • Our data suggest that defective PC1/3 expression may lead to preferential production of unprocessed, biologically inactive ACTH variants in SCA.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. Proprotein Convertase 1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917309.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Protein Isoforms; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.21.93 / Proprotein Convertase 1
  •  go-up   go-down


5. Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P: [Use of cabergoline in persisting Cushing's disease]. Ann Endocrinol (Paris); 2006 Sep;67(4):353-6
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Utilisation de la cabergoline dans la maladie de Cushing non contrôlée.
  • Cabergoline is a dopaminergic agonist with demonstrated efficiency of for the treatment of prolactin-secreting pituitary tumors.
  • We describe the use of cabergoline in three patients with Cushing's disease, one of them presenting a silent ACTH-secreting pituitary tumor.
  • We describe a decrease or a normalization in hypercortisolism; for one of the subjects, tumor growth seemed to be stopped.
  • While cabergoline can induce a suppression of cortisol secretion or a corticotroph tumor shrinkage, the sites of action remain unclear.
  • [MeSH-major] Adrenocortical Hyperfunction / drug therapy. Ergolines / therapeutic use. Pituitary ACTH Hypersecretion / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072242.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; LL60K9J05T / cabergoline; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


6. Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S: Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem; 2005 Jun 24;280(25):24011-21
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.
  • Somatostatin inhibits adrenocorticotropin (ACTH) secretion from pituitary tumor cells.
  • Although octreotide had similar inhibiting potency (picomolar) for cAMP accumulation and ACTH secretion as an SST2-selective agonist, somatostatin-28 exhibited a higher potency (femtomolar).
  • This may explain superior somatostatin-28 potency and provides a rationale for somatostatin ligand design to treat ACTH-secreting pituitary tumors.
  • [MeSH-minor] Adenoma / secretion. Animals. Base Sequence. Blotting, Western. Cell Line, Tumor. DNA Primers. Immunoprecipitation. Mice. Microscopy, Confocal. Microscopy, Fluorescence. Pituitary Neoplasms / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857828.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


7. Pimentel-Filho FR, Silva ME, Nogueira KC, Berger K, Cukiert A, Liberman B: Pituitary-adrenal dynamics after ACTH-secreting pituitary tumor resection in patients receiving no steroids post-operatively. J Endocrinol Invest; 2005 Jun;28(6):502-8
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary-adrenal dynamics after ACTH-secreting pituitary tumor resection in patients receiving no steroids post-operatively.
  • We compared the dynamics of ACTH and cortisol from a group of CD patients (cured and not cured), receiving no steroids post-operatively, with a control group of acromegalic patients who presented normal hypothalamic-pituitary-adrenal (HPA) axis.
  • Blood samples for ACTH and cortisol determination were obtained immediately before, at the end of surgery and at 4, 8, 12, 16, 24, 48 and 72 h after surgery, in 8 cured CD patients (Group I), 9 not cured CD patients (Group II) and in 7 subjects with acromegaly (Group III) who presented normal HPA axis (control group).
  • The mean ACTH level in Group I was significantly lower than in Group III from 4 to 12 h and lower than in Group II from 8 to 12 h post-operatively.
  • [MeSH-major] Adrenal Glands / physiopathology. Adrenocorticotropic Hormone / secretion. Glucocorticoids / administration & dosage. Pituitary Gland / physiopathology. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adenoma / physiopathology. Adenoma / secretion. Adenoma / surgery. Adrenal Insufficiency / drug therapy. Adrenal Insufficiency / etiology. Adult. Female. Humans. Hydrocortisone / blood. Male. Pituitary ACTH Hypersecretion / physiopathology. Pituitary ACTH Hypersecretion / surgery. Postoperative Care. Postoperative Complications. Time Factors

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1776-9 [9177381.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Feb;36(2):151-9 [1314723.001]
  • [Cites] Crit Care Med. 1988 Mar;16(3):296-7 [2830078.001]
  • [Cites] J Endocrinol Invest. 2001 Feb;24(2):83-7 [11263476.001]
  • [Cites] Proc R Soc Med. 1965 Jan;58:55-61 [14267501.001]
  • [Cites] J Clin Invest. 1986 Apr;77(4):1377-81 [3958189.001]
  • [Cites] Circ Res. 1969 Mar;24(3):383-95 [5766517.001]
  • [Cites] Surg Gynecol Obstet. 1990 Jun;170(6):513-6 [2343366.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2745-50 [12050244.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Jan;38(1):73-8 [8435888.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1131-9 [15001598.001]
  • [Cites] J Trauma. 1992 Jan;32(1):94-100 [1732582.001]
  • [Cites] Br J Pharmacol. 1970 Nov;40(3):528-30 [5497802.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):1036-9 [7883819.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Jan;44(1):1-6 [8706280.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):348-54 [8045946.001]
  • [Cites] Intensive Care Med. 1991;17(4):238-40 [1744311.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Feb;54(2):413-22 [6274904.001]
  • [Cites] Intensive Care Med. 1994;20(2):138-41 [8201094.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):912-6 [2541160.001]
  • [Cites] J Clin Endocrinol Metab. 1987 May;64(5):986-94 [3031124.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Apr;40(4):675-87 [165214.001]
  • [Cites] Pharmacotherapy. 1988;8(1):69-71 [3375132.001]
  • [Cites] Ann Surg. 1994 Apr;219(4):416-25 [8161268.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):1-8 [11453376.001]
  • (PMID = 16117190.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


8. Vik-Mo EO, Øksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M: Gamma knife stereotactic radiosurgery of Nelson syndrome. Eur J Endocrinol; 2009 Feb;160(2):143-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Gamma knife radiosurgery (GKR) can be used as primary or adjuvant therapy for the treatment of an ACTH-producing pituitary tumor after bilateral adrenalectomy, called Nelson syndrome (NS).
  • We have examined the effect of GKR on tumor growth and ACTH-hypersecretion, and characterized the adverse events of this treatment in patients with NS.
  • RESULTS: Tumor growth was stopped in all patients.
  • The ACTH levels declined in eight patients, and normalized in one patient.
  • There was a significant drop in ACTH levels, with a half-time of 2.8 years.
  • The substitution therapy of three pituitary axes present at GKR treatment could be stopped during the same period.
  • As the radiation level was below 1Gy to this area, it is unlikely that the GKR treatment itself induced the malignant tumor.

  • Genetic Alliance. consumer health - Nelson syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996962.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


9. Liu JK, Fleseriu M, Delashaw JB Jr, Ciric IS, Couldwell WT: Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus; 2007;23(3):E8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cushing disease is considered an aggressive pituitary endocrinopathy because of the devastating effects from untreated hypercortisolemia.
  • Although they are histologically benign, these adrenocorticotropic hormone (ACTH)-secreting pituitary tumors are associated with significant morbidity and premature death.
  • Currently, transsphenoidal surgery is the primary treatment of Cushing disease associated with an ACTH-secreting pituitary tumor, resulting in remission rates ranging from about 50 to 90%.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / surgery. Adenoma / surgery. Pituitary ACTH Hypersecretion / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961031.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


10. Castillo V, Giacomini D, Páez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E: Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology; 2006 Sep;147(9):4438-44
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cushing's disease is almost always caused by an ACTH-secreting pituitary tumor, but effective medical therapy is currently limited.
  • Clinical signs, plasma ACTH and alpha-MSH, the cortisol/creatinine urine ratio, and pituitary magnetic resonance imaging were assessed and compared at different time points.
  • We recorded a significant reduction in plasma ACTH and alpha-MSH, and also in the cortisol/creatinine urine ratio, of the dogs treated with retinoic acid.
  • Pituitary adenoma size was also significantly reduced at the end of retinoic acid treatment.
  • Retinoic acid treatment controls ACTH and cortisol hyperactivity and tumor size in dogs with ACTH-secreting tumors, leading to resolution of the clinical phenotype.
  • This study highlights the possibility of using retinoic acid as a novel therapy in the treatment of ACTH-secreting tumors in humans with Cushing's disease.
  • [MeSH-major] Dog Diseases / drug therapy. Pituitary ACTH Hypersecretion / veterinary. Tretinoin / therapeutic use
  • [MeSH-minor] Adenoma / pathology. Adrenocorticotropic Hormone / blood. Animals. Body Weight. Creatinine / urine. Dogs. Female. Hydrocortisone / urine. Ketoconazole / therapeutic use. Magnetic Resonance Imaging / veterinary. Male. Pituitary Gland / pathology. Pituitary Neoplasms / pathology. Survival Rate. alpha-MSH / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740975.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 581-05-5 / alpha-MSH; 9002-60-2 / Adrenocorticotropic Hormone; AYI8EX34EU / Creatinine; R9400W927I / Ketoconazole; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


11. Amaral FC, Torres N, Saggioro F, Neder L, Machado HR, Silva WA Jr, Moreira AC, Castro M: MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab; 2009 Jan;94(1):320-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.
  • OBJECTIVE: The aim of the study was to analyze the differential expression of let-7a, miR-15a, miR-16, miR-21, miR-141, miR-143, miR-145, and miR-150 in corticotropinomas and normal pituitary tissue and verify whether their profile of expression correlates with tumor size or remission after treatment.
  • MATERIAL AND METHODS: ACTH-secreting pituitary tumor samples were obtained during transphenoidal surgery from patients with Cushing disease and normal pituitary tissues from autopsies.
  • RESULTS: We found underexpression of miR-145 (2.0-fold; P = 0.04), miR-21 (2.4-fold; P = 0.004), miR-141 (2.6-fold; P = 0.02), let-7a (3.3-fold; P = 0.003), miR-150 (3.8-fold; P = 0.04), miR-15a (4.5-fold; P = 0.03), miR-16 (5.0-fold; P = 0.004), and miR-143 (6.4-fold; P = 0.004) in ACTH-secreting pituitary tumors when compared to normal pituitary tissues.
  • There were no differences between miRNA expression and tumor size as well as miRNA expression and ratio of remission after surgery, except in patients presenting lower miR-141 expression who showed a better chance of remission.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. MicroRNAs / analysis
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Pituitary ACTH Hypersecretion / genetics. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840638.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


12. Suri D, Weiss RE: Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab; 2005 Mar;90(3):1340-6
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peroxisomal proliferator-activated receptors (PPAR)-gamma are abundantly expressed in ACTH-secreting pituitary tumors.
  • Treatment with PPARgamma agonists inhibits ACTH-secreting pituitary tumor growth, proliferation, and ACTH secretion in vitro in human and murine models and in vivo in murine corticotroph tumors.
  • It was hypothesized that treatment with the PPARgamma agonist pioglitazone would normalize the hypothalamic-pituitary-adrenal axis of patients with CD.
  • We evaluated the hypothalamic pituitary adrenal axis in five patients with CD in whom we measured:.
  • 2) the 24-h profile of serum cortisol and plasma ACTH; and 3) the ACTH and cortisol response to CRH stimulation.
  • At baseline, before low-dose dexamethasone, all five patients had elevated 24-h urine free cortisol, elevated 24-h serum cortisol and plasma ACTH levels, and robust responses to CRH, consistent with their diagnosis of CD.
  • Furthermore, there was no significant difference in the number of cortisol or ACTH spikes or in their diurnal rhythms.
  • In summary, pioglitazone treatment (45 mg daily for 30 d) of patients with CD was not found to be effective at attenuating either ACTH or cortisol levels and does not appear to be an alternative to surgical therapy.
  • [MeSH-major] Adrenocorticotropic Hormone / blood. Hydrocortisone / blood. Hypoglycemic Agents / administration & dosage. Pituitary ACTH Hypersecretion / drug therapy. Pituitary ACTH Hypersecretion / metabolism. Thiazolidinediones / administration & dosage
  • [MeSH-minor] Adult. Circadian Rhythm. Female. Humans. Hypothalamo-Hypophyseal System / drug effects. Male. Middle Aged. PPAR gamma / metabolism. Pituitary-Adrenal System / drug effects. Treatment Failure

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. PIOGLITAZONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585550.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 58258; United States / NIDDK NIH HHS / DK / DK07011; United States / NIDDK NIH HHS / DK / DK17050; United States / NIDDK NIH HHS / DK / DK58258; United States / NCRR NIH HHS / RR / RR00055; United States / NCRR NIH HHS / RR / RR18372
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone; X4OV71U42S / pioglitazone
  •  go-up   go-down


13. Pollock BE, Brown PD, Nippoldt TB, Young WF Jr: Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery; 2008 Jun;62(6):1271-6; discussion 1276-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas.
  • OBJECTIVE: Reported biochemical remission rates have ranged widely after stereotactic radiosurgery for patients with hormone-secreting pituitary adenomas.
  • Confounding variables include histology, radiation dose, use of pituitary-suppressive medications, and length of follow-up.
  • METHODS: A retrospective review of 46 patients with pituitary adenomas (growth hormone-secreting, n = 27; prolactin-secreting, n = 11; adrenocorticotropin-secreting, n = 8) undergoing radiosurgery between January 1990 and December 2003 was conducted.
  • All received a tumor margin dose of 18 Gy or more and were off pituitary-suppressive medications for at least 1 month before radiosurgery.
  • Patients with oversecretion of adrenocorticotropin or growth hormone were more likely to achieve remission after radiosurgery than patients with prolactinomas (hazard ratio, 4.4; 95% confidence interval, 1.1-18.2; P = 0.04).
  • Of 44 patients with normal or partial anterior pituitary function before radiosurgery, 16 (36%) developed one or more new anterior pituitary deficits.
  • The incidence of new anterior pituitary deficits was 26% at 4 years.
  • CONCLUSION: There seems to be a differential sensitivity after radiosurgery for hormone-secreting pituitary adenomas.
  • [MeSH-major] Adenoma / metabolism. Adenoma / surgery. Pituitary Hormones / metabolism. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2010 May;66(5):E1030; author reply E1030 [20404679.001]
  • (PMID = 18824993.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


14. Batista D, Courkoutsakis NA, Oldfield EH, Griffin KJ, Keil M, Patronas NJ, Stratakis CA: Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease. J Clin Endocrinol Metab; 2005 Sep;90(9):5134-40
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease.
  • CONTEXT: We recently showed that pre- and postcontrast spoiled gradient-recalled acquisition in the steady-state (SPGR) was superior to conventional pre- and postcontrast T-1 weighted spin echo (SE) acquisition magnetic resonance imaging (MRI) for the diagnostic evaluation of pituitary tumors in adult patients.
  • OBJECTIVE: The present investigation assessed the use of SPGR vs. SE-MRI in the diagnostic evaluation of ACTH-secreting tumors in children and adolescents with Cushing disease.
  • Postcontrast SPGR-MRI identified the location of the tumor in 18 of 28 patients, whereas postcontrast SE-MRI identified the location and accurately estimated the size of the tumor in only five patients (P < 0.001).
  • CONCLUSIONS: We conclude that conventional MRI, even with contrast enhancement, mostly failed to identify ACTH-secreting microadenomas in children and adolescents with Cushing disease.
  • Postcontrast SPGR-MRI was superior to SE-MRI and should be used in addition to conventional SE-MRI in the pituitary evaluation of children and adolescents with suspected Cushing disease.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / secretion. Adrenocorticotropic Hormone / secretion. Cushing Syndrome / diagnosis. Magnetic Resonance Imaging. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941871.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


15. Tateno T, Kato M, Tani Y, Yoshimoto T, Oki Y, Hirata Y: Processing of high-molecular-weight form adrenocorticotropin in human adrenocorticotropin-secreting tumor cell line (DMS-79) after transfection of prohormone convertase 1/3 gene. J Endocrinol Invest; 2010 Feb;33(2):113-7
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Processing of high-molecular-weight form adrenocorticotropin in human adrenocorticotropin-secreting tumor cell line (DMS-79) after transfection of prohormone convertase 1/3 gene.
  • Ectopic ACTH-producing tumors preferentially secrete biologically inactive ACTH precursors and ACTH-related fragments.
  • DMS-79 is known to secrete unprocessed high-molecular-weight (HMW) form ACTH.
  • Molecular weights of ACTH-related peptides were determined by chromatographical analyses coupled with ACTH and beta-endorphin (beta-END) radioimmunoassays.
  • The steady-state mRNA levels of PC1/3 and 2 in DMS-79 were lower than those in ACTH-secreting and nonfunctioning pituitary tumors.
  • DMS-79 predominantly secreted HMW form with both ACTH and beta-END immunoreactivities by size-exclusion chromatography.
  • After purification by immunoaffinity chromatography with anti-ACTH antibody, the apparent molecular weight of HMW form ACTH was estimated to be 16 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with silver staining.
  • After retroviral transfection of PC1/3 cDNA into DMS-79 and puromycin selection, PC1/3 stably-expressing cell line (DMS-79T) secreted two immunoreactive ACTH components, a major one coeluting with ACTH(1-39) and a minor one as a HMW form as well as two beta- END immunoreactive components coeluting with beta-lipotropic hormone and beta-END, respectively.
  • Thus, we have established PC1/3 stably-expressing cell line (DMS-79T) capable of proteolytically processing ACTH precursor molecule(s) into mature ACTH and beta-END.
  • [MeSH-minor] Adenoma / secretion. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Humans. Lung Neoplasms. Molecular Weight. Pituitary Neoplasms / secretion. Proprotein Convertase 2 / genetics. Proprotein Convertase 2 / metabolism. RNA, Messenger / analysis. Retroviridae / genetics. Small Cell Lung Carcinoma. Transfection. beta-Endorphin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 15;201(2):795-804 [8003017.001]
  • [Cites] Eur J Endocrinol. 2007 Dec;157(6):717-24 [18057378.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):251-5 [9578811.001]
  • [Cites] Curr Opin Chem Biol. 1998 Feb;2(1):31-9 [9667917.001]
  • [Cites] DNA Cell Biol. 1990 Dec;9(10):789 [2264933.001]
  • [Cites] J Neurosurg. 2004 Nov;101(5):874-7 [15540932.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jul;41(1):106-14 [168226.001]
  • [Cites] J Biol Chem. 1977 Dec 25;252(24):8821-32 [200620.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1503-6 [7962350.001]
  • [Cites] Ann N Y Acad Sci. 1999 Oct 20;885:57-74 [10816641.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1289-96 [6261922.001]
  • [Cites] Endocr J. 2001 Feb;48(1):43-51 [11403102.001]
  • [Cites] Cell Biol Int. 2006 Mar;30(3):270-7 [16406822.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):737-45 [8006087.001]
  • [Cites] Endocrinology. 2007 Sep;148(9):4201-7 [17584964.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Oct;75(10):5160-4 [217015.001]
  • [Cites] Eur J Endocrinol. 2003 Aug;149(2):79-90 [12887283.001]
  • [Cites] Endocr J. 2005 Dec;52(6):743-50 [16410667.001]
  • [Cites] Endocr J. 2007 Dec;54(5):777-82 [17917309.001]
  • [Cites] Mol Cell Neurosci. 1994 Dec;5(6):614-22 [7704436.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jan;44(1):214-7 [188860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3564-8 [2023902.001]
  • [Cites] Mol Endocrinol. 1992 Mar;6(3):485-97 [1316544.001]
  • [Cites] Mol Endocrinol. 1999 Aug;13(8):1353-63 [10446908.001]
  • [Cites] Clin Endocrinol (Oxf). 1980 May;12(5):491-524 [6253108.001]
  • [Cites] J Endocrinol. 1986 Jan;108(1):49-56 [3003221.001]
  • (PMID = 19786827.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RNA, Messenger; 60617-12-1 / beta-Endorphin; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.21.93 / Proprotein Convertase 1; EC 3.4.21.94 / Proprotein Convertase 2
  •  go-up   go-down


16. Bush ZM, Lopes MB, Hussaini IM, Jane JA Jr, Laws ER Jr, Vance ML: Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. Pituitary; 2010;13(1):1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cushing's disease is caused by an ACTH-producing pituitary tumor, and accounts for 10-15% of pituitary tumors.
  • The majority of corticotroph tumors are microadenomas (<10 mm), and accurate histologic identification of these tumors can be challenging because of their small size and the presence of nests of normal corticotroph cells in the anterior pituitary.
  • Retinoic acid has been shown to inhibit ACTH production and induce apoptosis in corticotroph tumor cells.
  • The expression of the orphan nuclear receptor COUP-TFI antagonizes retinoic acid signaling and has been shown to be expressed in normal corticotroph cells, but absent in corticotroph tumor cell lines.
  • We analyzed 34 corticotroph tumor specimens by immunohistochemistry using a goat polyclonal IgG antibody with epitope mapping to the N-terminus of human COUP-TFI.
  • Segments of normal pituitary in each of the 34 specimens demonstrate COUP-TFI immunoreactivity in normal corticotroph cells.
  • Twenty-nine of 34 ACTH producing tumors were immunonegative for COUP-TFI.
  • Immunohistochemistry of COUP-TFI may be a useful adjuvant diagnostic tool in distinguishing corticotroph microadenomas from nests of normal corticotroph cells in the anterior pituitary.
  • Furthermore, this study identifies two unique corticotroph tumor populations which differ in their expression of COUP-TFI, the presence of which occurs more frequently in macroadenomas.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / diagnosis. Adenoma / diagnosis. COUP Transcription Factor I / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Oct;91(10):3746-53 [16868050.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2681-6 [9709931.001]
  • [Cites] Cell. 1995 Dec 15;83(6):841-50 [8521508.001]
  • [Cites] Endocr Rev. 1999 Apr;20(2):136-55 [10204115.001]
  • [Cites] Exp Cell Res. 2000 May 1;256(2):545-54 [10772826.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Jul;51(1):67-71 [10468967.001]
  • [Cites] Endocr Rev. 1998 Oct;19(5):647-72 [9793762.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1427-33 [1977759.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Feb;93(2):358-62 [18056770.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Mol Cell Biol. 1995 Feb;15(2):1034-48 [7823919.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602 [14671138.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1448-52 [1311101.001]
  • [Cites] J Clin Invest. 2001 Oct;108(8):1123-31 [11602619.001]
  • [Cites] Clin Genet. 2007 Sep;72(3):175-82 [17718852.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):2-3 [16929356.001]
  • [Cites] J Am Coll Surg. 2001 Dec;193(6):651-9 [11768682.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):553-8; discussion 558-9 [10719850.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4 [8380496.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1605-17 [16698415.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4438-44 [16740975.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] J Pathol. 1994 Aug;173(4):371-9 [7965396.001]
  • [Cites] Stain Technol. 1974 May;49(3):153-5 [4135794.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):520-7 [2552045.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3114-20 [7593411.001]
  • [Cites] Cell Mol Life Sci. 2000 Sep;57(10):1388-98 [11078018.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5808-13 [14671173.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4515-21 [12364428.001]
  • [Cites] Am J Clin Pathol. 1981 Jun;75(6):816-21 [6167159.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):211-22 [10207692.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):121-7 [11761429.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Jun;49(4-6):261-7 [8043488.001]
  • (PMID = 19526345.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 1-T32-DK-07646; United States / NIDDK NIH HHS / DK / T32 DK007646; United States / NCRR NIH HHS / RR / M01RR000847; United States / NIDDK NIH HHS / DK / 1-F32-DK082159-01; United States / NINDS NIH HHS / NS / 5R01NS035122-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COUP Transcription Factor I
  •  go-up   go-down


17. Martínez-Fuentes AJ, Moreno-Fernández J, Vázquez-Martínez R, Durán-Prado M, de la Riva A, Tena-Sempere M, Diéguez C, Jiménez-Reina L, Webb SM, Pumar A, Leal-Cerro A, Benito-López P, Malagón MM, Castaño JP: Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomas. J Clin Endocrinol Metab; 2006 Jun;91(6):2225-31
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomas.
  • CONTEXT: In Cushing's disease, ACTH hypersecretion by pituitary corticotrope adenoma cells and resulting hypercortisolism is accompanied by a severely blunted GH secretory response.
  • Interestingly, in Cushing's disease, ghrelin markedly increases plasma ACTH, whereas its stimulatory action on GH secretion is reduced.
  • Although the reported expression of ghrelin receptors (GHS-R) in corticotrope tumors offers a potential mechanism for ghrelin-induced ACTH hypersecretion, studies on the direct effects of synthetic GH secretagogues on corticotropinoma cells offered contradictory results.
  • Importantly, double immunogold electron microscopy revealed that ghrelin is costored within ACTH secretory vesicles in densely granulated adenomatous corticotropes.
  • CONCLUSIONS: These results constitute the first demonstration that ghrelin acts directly on corticotrope tumor cells derived from patients with Cushing's disease.
  • The presence of ghrelin and GHS-R suggests that pituitary ghrelin may play an autocrine/paracrine role in regulating ACTH release in Cushing's disease.
  • Our findings provide a plausible cellular basis for the exaggerated ACTH response to ghrelin in Cushing's disease and suggest novel research strategies to develop medical treatments for this disease.
  • [MeSH-major] Adenoma / secretion. Adrenocorticotropic Hormone / secretion. Peptide Hormones / physiology. Pituitary Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551736.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Ghrelin; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; SY7Q814VUP / Calcium
  •  go-up   go-down


18. Iino K, Oki Y, Yamashita M, Matsushita F, Hayashi C, Yogo K, Nishizawa S, Yamada S, Maekawa M, Sasano H, Nakamura H: Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma. J Clin Endocrinol Metab; 2010 Aug;95(8):4003-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible relevance between prohormone convertase 2 expression and tumor growth in human adrenocorticotropin-producing pituitary adenoma.
  • CONTEXT: Methods for preoperative diagnosis of prohormone convertase 2 (PC2)-positive ACTH-producing pituitary adenomas (APPAs) have not been established.
  • CONCLUSIONS: Our study suggests that PC2 expression and Akt phosphorylation are related at the molecular level, resulting in a change in cell cycle and an increase in pituitary adenoma size.
  • An elevation of plasma alphaMSH could conjecture the activation of the phosphatidylinositol 3/Akt cascade in PC2-positive APPAs and may become a valuable clinical marker of tumor growth in Cushing's disease.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / metabolism. Adenoma / metabolism. Proprotein Convertase 2 / metabolism. alpha-MSH / blood

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501680.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 581-05-5 / alpha-MSH; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.21.94 / Proprotein Convertase 2
  •  go-up   go-down


19. Sakihara S, Kageyama K, Matsumoto A, Ikeda H, Tsushima Y, Naraoka M, Terui K, Nigawara T, Suda T: Exaggerated response of adrenocorticotropic hormone to growth hormone-releasing peptide-2 test in Cushing's disease. Case report. Neurol Med Chir (Tokyo); 2009 Aug;49(8):365-9
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old woman presented with a pituitary microadenoma manifesting as typical Cushing's syndrome.
  • Plasma adrenocorticotropic hormone (ACTH) levels were greatly increased from 66 pg/ml to 2490 pg/ml (about 38-fold) in response to the administration of 100 microg human growth hormone-releasing peptide (GHRP)-2.
  • GHRP receptor type 1a messenger ribonucleic acid was detected in the tumor.
  • Therefore, GHRP-2 may stimulate ACTH via the GHRP receptor type 1a in pituitary ACTH-producing tumor.
  • [MeSH-major] Adenoma / metabolism. Adrenocorticotropic Hormone / blood. Oligopeptides. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / physiopathology. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Biomarkers / analysis. Biomarkers / blood. Female. Humans. Hypothalamo-Hypophyseal System / metabolism. Hypothalamo-Hypophyseal System / physiopathology. Hypothalamo-Hypophyseal System / secretion. Middle Aged. Pituitary-Adrenal System / metabolism. Pituitary-Adrenal System / physiopathology. Pituitary-Adrenal System / secretion. Predictive Value of Tests. RNA, Messenger / metabolism. Receptors, Neuropeptide / genetics. Receptors, Pituitary Hormone-Regulating Hormone / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707004.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Oligopeptides; 0 / RNA, Messenger; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / growth hormone-releasing peptide-2; 0 / somatocrinin receptor; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


20. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A: The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab; 2006 Nov;91(11):4482-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
  • CONTEXT: There is no tumor-directed medical therapy available for Cushing's disease.
  • SOM230 effects on cell proliferation and ACTH release were evaluated in vitro using primary cultures of six of the 13 human corticotroph adenomas.
  • SOM230 inhibited ACTH secretion in five of the six tumors cultured (percent suppression range: 23-56%; P = 0.042-0.001).
  • SOM230 significantly suppressed cell proliferation and ACTH secretion in primary cultures of human corticotroph tumors.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Adenoma / drug therapy. Adrenocorticotropic Hormone / secretion. Cell Proliferation / drug effects. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Immunohistochemistry. In Vitro Techniques. Male. Middle Aged. Pituitary ACTH Hypersecretion / drug therapy. RNA, Messenger / metabolism. Receptors, Somatostatin / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940446.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; 98H1T17066 / pasireotide
  •  go-up   go-down


21. Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovācs G, Korbonits M, Scheithauer BW, Kovacs K, Lloyd RV: MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine; 2010 Aug;38(1):67-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.
  • MicroRNAs (miRNAs) are involved in cell proliferation, differentiation, and apoptosis, and can function as tumor suppressor genes or oncogenes.
  • The expression of miRNAs in pituitary carcinomas has not been previously examined.
  • We used miRNA profiling with 1,145 probes to study miRNA expression in normal anterior pituitary (6 cases), adrenocorticotropin (ACTH)-producing adenomas (8 cases), and ACTH-producing pituitary carcinomas (two cases).
  • Real-time RT-PCR and in situ hybridization were used to confirm and independently validate miRNAs that were significantly up-regulated or down-regulated between the pituitary tissues.
  • Both real-time RT-PCR and in situ hybridization showed significant up-regulation of miRNA-122 between pituitary carcinomas and adenomas.
  • MiRNA-493 was also up-regulated in carcinomas compared to ACTH adenomas.
  • Analysis of genes that miRNA-493 interacts with included LGALS3 and RUNX2 ( http://microrna.sanger.ac.uk ) both of which have been shown to have roles in pituitary tumor cell growth.
  • These results provide information about marker miRNAs that may lead to further insights into the regulation of pituitary tumor growth and development.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. In Situ Hybridization. Oligonucleotide Array Sequence Analysis. Pituitary Gland, Anterior / pathology. Pituitary Gland, Anterior / physiology. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):320-3 [18840638.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6188-96 [17028598.001]
  • [Cites] Bioinformatics. 2004 Nov 1;20(16):2778-86 [15166021.001]
  • [Cites] RNA. 2006 Feb;12(2):187-91 [16373485.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Endocrine. 2009 Feb;35(1):101-11 [19020999.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]
  • [Cites] Curr Biol. 2002 Apr 30;12(9):735-9 [12007417.001]
  • [Cites] J Biol Chem. 2009 Nov 13;284(46):32015-27 [19726678.001]
  • [Cites] Scand J Gastroenterol. 2009;44(11):1332-9 [19891584.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):107-14 [16199895.001]
  • [Cites] Methods. 2008 Jan;44(1):39-46 [18158131.001]
  • [Cites] Semin Reprod Med. 2008 Nov;26(6):453-60 [18951327.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1375-7 [17072315.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):25-39, vi [12690977.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):728-38 [17724137.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1136-40 [15734994.001]
  • [Cites] BMC Genomics. 2007 Jun 15;8:172 [17573962.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):97-103 [11463446.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Biomed Environ Sci. 2009 Feb;22(1):14-21 [19462682.001]
  • [Cites] Science. 2010 Jan 8;327(5962):198-201 [19965718.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):685-9 [16258535.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2251-5 [12727847.001]
  • [Cites] Development. 2005 Nov;132(21):4645-52 [16224044.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):969-77 [18098138.001]
  • [Cites] RNA. 2005 Nov;11(11):1745-8 [16177135.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):818-24 [9062489.001]
  • [Cites] Neurosurgery. 2005 May;56(5):1066-74; discussion 1066-74 [15854256.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):648-56 [18291553.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):431-41 [19136928.001]
  • (PMID = 20960104.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN122 microRNA, human; 0 / MIRN493 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


22. Paez-Pereda M, Kuchenbauer F, Arzt E, Stalla GK: Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix. Braz J Med Biol Res; 2005 Oct;38(10):1487-94
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix.
  • The extracellular matrix conveys signals through membrane receptors called integrins and plays an important role in pituitary physiology and tumorigenesis.
  • There is a differential expression of extracellular matrix components and integrins during the pituitary development in the embryo and during tumorigenesis in the adult.
  • Different extracellular matrix components regulate adrenocorticotropin at the level of the proopiomelanocortin gene transcription.
  • The extracellular matrix also controls the proliferation of adrenocorticotropin-secreting tumor cells.
  • Laminin has a dynamic pattern of expression during prolactinoma development with lower levels in the early pituitary hyperplasia and a strong reduction in fully grown prolactinomas.
  • Therefore, the expression of extracellular matrix components plays a role in pituitary tumorigenesis.
  • On the other hand, the remodeling of the extracellular matrix affects pituitary cell proliferation.
  • Matrix metalloproteinase activity is very high in all types of human pituitary adenomas.
  • Matrix metalloproteinase secreted by pituitary cells can release growth factors from the extracellular matrix that, in turn, control pituitary cell proliferation and hormone secretion.
  • In summary, the differential expression of extracellular matrix components, integrins and matrix metalloproteinase contributes to the control of pituitary hormone production and cell proliferation during tumorigenesis.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172741.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 0 / Integrins; 0 / Pituitary Hormones; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 54
  •  go-up   go-down


23. Gondim JA, Schops M, de Almeida JP, de Albuquerque LA, Gomes E, Ferraz T, Barroso FA: Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary; 2010;13(1):68-77
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center.
  • Pituitary tumors are challenging tumors in the sellar region.
  • Surgical approaches to the pituitary have undergone numerous refinements over the last 100 years.
  • The introduction of the endoscope have revolutionized pituitary surgery.
  • The aim of this study is to report the results of a consecutive series of patients undergoing pituitary surgery using a pure endoscopic endonasal approach and to evaluate the efficacy and safety of this procedure.
  • Tumor removal rate, endocrinological outcomes, and complications were retrospectively assessed in 228 patients with pituitary adenomas who underwent 251 procedures between December 1998 and December 2007.
  • There were 93 nonfunctioning adenomas, 58 growth hormone-secreting, 41 prolactin-secreting, 28 adrenocorticotropin hormone secreting, 7 FSH-LH secreting and 1 thyroid-stimulating hormone-secreting adenomas.
  • The remission results for patients with nonfunctioning adenomas was 83% and for functioning adenomas were 76.3% (70.6% for GH hormone-secreting, 85.3% for prolactin hormone-secreting, 71.4% for ACTH hormone-secreting, 85.7% for FSH-LH hormone-secreting and 100% for TSH hormone-secreting), with no recurrence at the time of the last follow-up.
  • The endoscopic endonasal approach for resection of pituitary adenomas, provides acceptable results representing a safe alternative procedure to the microscopic approach.
  • This less invasive method, associated with a small number of complications, provides excellent tumor removal rates and represents an important tool for the achievement of good results in the pituitary surgery, mainly for the complete removal of large adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Humans. Pituitary Hormones / blood. Postoperative Complications. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):737-40 [16322377.001]
  • [Cites] Neurosurgery. 2004 May;54(5):1043-48; discussions 1048-50 [15113457.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1882-6 [17003708.001]
  • [Cites] Minim Invasive Neurosurg. 2005 Dec;48(6):348-54 [16432784.001]
  • [Cites] Am J Otolaryngol. 2008 Jan-Feb;29(1):48-50 [18061832.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2000 Apr;63(4):301-10 [10820909.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Sep;61(3B):836-41 [14595492.001]
  • [Cites] Laryngoscope. 1984 Aug;94(8):1066-74 [6379349.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):70-5 [8315471.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):933-40; discussion 940-1 [15458602.001]
  • [Cites] Monatsschr Ohrenheilkd Laryngorhinol. 1970;104(10):451-6 [5478133.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6348-57 [15579802.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):240-8 [17047389.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(12):1416-25 [9030348.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Jun;41(2):66-73 [9651913.001]
  • [Cites] Clin Neurol Neurosurg. 2009 Feb;111(2):119-22 [18986756.001]
  • [Cites] Neurosurgery. 2008 May;62(5):1006-15; discussion 1015-7 [18580798.001]
  • [Cites] J Neurosurg. 1981 Apr;54(4):448-54 [7009800.001]
  • [Cites] Horm Res. 1985;22(3):222-7 [4054842.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):187-95 [11761435.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):353-8 [9724106.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):225-36; discussion 236-7 [9007854.001]
  • [Cites] J Neurosurg. 1997 Jul;87(1):44-51 [9202264.001]
  • [Cites] Br Med J (Clin Res Ed). 1985 Nov 30;291(6508):1547-50 [3933746.001]
  • [Cites] Laryngoscope. 1992 Feb;102(2):198-202 [1738293.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Eur J Endocrinol. 2006 May;154(5):675-84 [16645014.001]
  • [Cites] Clin Neurosurg. 1969;16:185-217 [5811707.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):293-8 [12186456.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):226-31; discussion 231-2 [9482172.001]
  • [Cites] J Neurosurg. 1999 Aug;91(2):175-9 [10433303.001]
  • [Cites] Surg Neurol. 2002 Dec;58(6):371-5; discussion 375-6 [12517610.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):219-24; discussion 224-5 [9482171.001]
  • [Cites] J R Soc Med. 1986 May;79(5):262-9 [3014145.001]
  • [Cites] Laryngoscope. 1999 Nov;109(11):1838-40 [10569418.001]
  • [Cites] Surg Neurol. 2009 Jul;72 (1):15-9; discussion 19 [18440607.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Oct;45(4):407-13 [8959078.001]
  • [Cites] Surg Neurol. 1997 Mar;47(3):213-22; discussion 222-3 [9068690.001]
  • [Cites] Mayo Clin Proc. 1999 Jul;74(7):661-70 [10405694.001]
  • [Cites] J Neurosurg. 2001 Dec;95(6):1083-96 [11765830.001]
  • (PMID = 19697135.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


24. Mortini P, Losa M, Barzaghi R, Boari N, Giovanelli M: Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery; 2005 Jun;56(6):1222-33; discussion 1233
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of transsphenoidal surgery in a large series of patients with pituitary adenoma.
  • OBJECTIVE: To report the efficacy and safety of microsurgical transsphenoidal surgery in a series of previously untreated patients with pituitary adenoma.
  • METHODS: One thousand one hundred forty consecutive patients undergoing transsphenoidal resection of a pituitary adenoma at our department from January 1990 through December 2002 were included in our study.
  • RESULTS: The most frequent tumor type was clinically nonfunctioning adenoma (NFPA) (33.2%), followed by growth hormone-secreting adenoma (28.1%), adrenocorticotropin-secreting adenoma (23.0%), prolactin-secreting adenoma (13.2%), and last, thyrotropin-secreting adenoma (2.5%).
  • There were 788 macroadenomas (69.1%), and in 233 patients (20.4%), the tumor invaded one or both cavernous sinuses.
  • CONCLUSION: Transsphenoidal surgery is an effective and safe treatment for most patients with pituitary adenoma and could be considered the first-choice therapy in all cases except for prolactinomas responsive to dopamine agonists.
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / methods. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Pituitary Hormones / metabolism. Postoperative Complications. Retrospective Studies. Treatment Outcome. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918938.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


25. Dehdashti AR, Ganna A, Karabatsou K, Gentili F: Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery; 2008 May;62(5):1006-15; discussion 1015-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series.
  • OBJECTIVE: The aim of this study was to report the results of a consecutive series of patients undergoing pituitary surgery using a pure endoscopic endonasal approach and to evaluate the efficacy and safety of this procedure.
  • PATIENTS AND METHODS: We reviewed 200 consecutive patients with pituitary adenoma who underwent purely endoscopic transsphenoidal resection of their lesions.
  • The patients' clinical outcomes, including remission rates, degrees of tumor removal, and complications, were evaluated and compared with a previous microscopic series.
  • RESULTS: There were 111 nonfunctioning adenomas and 34 growth hormone-secreting, 27 adrenocorticotropin hormone-secreting, 25 prolactin-secreting, and 3 thyroid-stimulating hormone-secreting adenomas.
  • After a median follow-up period of 19 months, the remission results for patients with functioning adenomas were 71% for growth hormone-secreting, 81% for adrenocorticotropin hormone-secreting, and 88% for prolactin-secreting adenomas, with no recurrence at the time of the last follow-up.
  • This compares with similar results reported from series using a standard microsurgical approach (growth hormone-secreting adenomas, 67%; adrenocorticotropin hormone-secreting adenomas, 78%; and prolactin-secreting adenomas, 62%).
  • Endoscopic surgery for recurrent or residual nonfunctioning adenomas that had been previously treated using a microscopic approach revealed in the majority of cases a more limited exposure during the initial surgery, frequently with incomplete tumor removal.
  • CONCLUSION: A purely endoscopic approach for pituitary adenoma treatment is a safe and effective alternative to the traditional microscopic procedure.
  • Although our results reveal excellent tumor-removal rates, comparable remission rates in functioning tumors, and a very low rate of complications, additional studies with longer follow-up periods are required to confirm whether this approach should be considered the preferred procedure for pituitary surgery.
  • [MeSH-major] Neuroendoscopy. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580798.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kajiwara K, Saito K, Yoshikawa K, Ideguchi M, Nomura S, Fujii M, Suzuki M: Stereotactic radiosurgery/radiotherapy for pituitary adenomas: a review of recent literature. Neurol Med Chir (Tokyo); 2010;50(9):749-55
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery/radiotherapy for pituitary adenomas: a review of recent literature.
  • The recent clinical results are reviewed of stereotactic radiosurgery/radiotherapy for the treatment of pituitary adenomas.
  • The outcomes of pituitary adenomas treated by stereotactic radiosurgery/radiotherapy with gamma knife, CyberKnife, or linear accelerator (LINAC) radiosurgery were evaluated from articles published after 2004.
  • Each study was evaluated for the number of patients, radiosurgical parameter (marginal dose), length of follow up, tumor growth control, rate of hormonal normalization in secretary adenomas, and adverse events.
  • After gamma knife radiosurgery, the tumor reduction rates varied from 42.3% to 89% in non-secreting adenomas.
  • However, the tumor control rates in non-secreting adenomas were more than 90% in most studies.
  • In growth hormone-secreting adenomas, the rates of insulin-like growth factor-1 normalization ranged from 36.9% to 82%.
  • In adrenocorticotropin-secreting adenomas, the rates for 24-hour urine free cortisol normalization ranged from 27.9% to 54%.
  • In prolactin-secreting adenomas, the prolactin normalization ranged from 17.4% to 50%.
  • Image-guided stereotactic radiosurgery/radiotherapy with the gamma knife, CyberKnife, or LINAC system is effective and safe against pituitary adenomas.
  • Careful long-term follow up of the patients is necessary because of long-term anti-tumor effects and delayed adverse events.
  • [MeSH-major] Adenoma / surgery. Outcome Assessment (Health Care) / methods. Pituitary Neoplasms / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885109.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Japan
  •  go-up   go-down


27. Dehdashti AR, Gentili F: Current state of the art in the diagnosis and surgical treatment of Cushing disease: early experience with a purely endoscopic endonasal technique. Neurosurg Focus; 2007;23(3):E9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Transsphenoidal pituitary surgery is the primary therapy for Cushing disease because of its potential to produce lasting remission without the need for long-term drug or hormone replacement therapy.
  • The authors evaluated the current role of pure endoscopic endonasal pituitary surgery in the treatment of Cushing disease.
  • Final histological results were consistent with adrenocorticotropin hormone (ACTH)-secreting adenoma in 20 patients.
  • Three patients presented with new anterior pituitary deficiency, but no one had permanent diabetes insipidus.
  • Treatment failure was attributable to involvement of the cavernous sinus in two patients, incomplete tumor removal in one, negative exploration in one, and nodular corticotroph hyperplasia of the pituitary gland in one.
  • CONCLUSIONS: Early results indicated that endoscopic endonasal surgery is a safe and effective treatment for ACTH-producing adenomas.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / surgery. Adenoma / surgery. Endoscopy. Paranasal Sinuses / surgery. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961027.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement